KCI produced the first product developed specifically for negative pressure wound therapy.

In October 2019, Acelity and its KCI subsidiaries worldwide were acquired by 3M for $6.7 billion, including assumption of debt and other adjustments.

[7] The therapeutic support systems developed and supplied by KCI are largely for the treatment and prevention of complications associated with patient immobility.

[10] KCI was founded in 1976 in San Antonio, Texas, by James R. Leininger, then an emergency room physician[11] who wanted to help prevent the pulmonary complications associated with immobility.

The growth in revenue allowed KCI to go public and trade on the New York Stock Exchange (NYSE) in 1988.